Century Therapeutics Inc - Asset Resilience Ratio
Century Therapeutics Inc (IPSC) has an Asset Resilience Ratio of 24.70% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Century Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Century Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Century Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Century Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $55.26 Million | 24.7% |
| Total Liquid Assets | $55.26 Million | 24.70% |
Asset Resilience Insights
- Good Liquidity Position: Century Therapeutics Inc maintains a healthy 24.70% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Century Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Century Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Century Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Century Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.70% | $55.26 Million | $223.70 Million | -12.34pp |
| 2024-12-31 | 37.05% | $130.85 Million | $353.22 Million | +2.28pp |
| 2023-12-31 | 34.77% | $125.41 Million | $360.69 Million | -12.76pp |
| 2022-12-31 | 47.53% | $231.23 Million | $486.54 Million | +9.47pp |
| 2021-12-31 | 38.05% | $166.43 Million | $437.38 Million | -7.41pp |
| 2020-12-31 | 45.46% | $48.54 Million | $106.78 Million | +4.23pp |
| 2019-12-31 | 41.23% | $37.48 Million | $90.90 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more